The disadvantage of using VDR-agonists is that they are not commonly used in individuals without CKD and therefore direct clinical translation of study findings is limited; however, positive findings would support any therapy (vitamin D3 or VDR-agonist) that raises 1,25(OH)2D levels or activates the VDR as an equal surrogate. This evidence concerns the gene VDR and chronic kidney disease.